View in EDS

Selpercatinib plus cemiplimab in RET positive medullary thyroid cancer patient with skin cancers.

Saved in:

Bibliographic Details
Title:	Selpercatinib plus cemiplimab in RET positive medullary thyroid cancer patient with skin cancers.
Authors:	Locati LD; Department of Internal Medicine and Medical Therapeutics, University of Pavia, Pavia, Italy.; Medical Oncology Unit, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy., Puce F; Department of Internal Medicine and Medical Therapeutics, University of Pavia, Pavia, Italy.; Medical Oncology Unit, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy., Amoroso V; Medical Oncology Unit, ASST Spedali Civili of Brescia, Brescia, Italy., Sottotetti F; Medical Oncology Unit, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy., Berruti A; Medical Oncology Unit, ASST Spedali Civili of Brescia, Brescia, Italy.; Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Source:	Tumori [Tumori] 2025 Dec; Vol. 111 (6), pp. NP12-NP15. Date of Electronic Publication: 2025 Nov 09.
Publication Type:	Journal Article; Case Reports
Journal Info:	Publisher: Sage Publications Country of Publication: United States NLM ID: 0111356 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2038-2529 (Electronic) Linking ISSN: 03008916 NLM ISO Abbreviation: Tumori Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	2038-2529
DOI:	10.1177/03008916251378278